Currently, several oral androgen receptor signalling inhibitors are available for the treatment of advanced prostate cancer. Quantification of plasma concentrations of these drugs is highly relevant for various purposes, such as Therapeutic Drug Monitoring (TDM) in oncology. Here, we report a liquid chromatography/tandem mass spectrometric (LC-MS/MS) method for the simultaneous quantification of abiraterone, enzalutamide, and darolutamide. The validation was performed according to the requirements of the U.S. Food and Drug Administration and European Medicine Agency. We also demonstrate the clinical applicability of the quantification of enzalutamide and darolutamide in patients with metastatic castration-resistant prostate cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2023.123752DOI Listing

Publication Analysis

Top Keywords

enzalutamide darolutamide
12
lc-ms/ms method
8
method simultaneous
8
simultaneous quantification
8
quantification abiraterone
8
abiraterone enzalutamide
8
prostate cancer
8
validation lc-ms/ms
4
quantification
4
darolutamide human
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!